Shuchi Nahar's Weekend Blog!

Trends to track in Healthcare Sector Wherever we look in the healthcare industry, we can find new technology being used to fight illness, develop new vaccines and medicines, and help people to live healthier lives. It is apparent that some pharmaceutical companies are starting to recognize the impact of the two major shifts: Downward pressure on pricing and the move towards prevention, diagnosis, and real cures. These changes are upsetting the established order, opening the door to new competition, and forcing companies to rethink where they play – and who they play with, requiring a growing emphasis on collaboration and partnership. Over the last two years, many tech companies have focused on applying their expertise to solve problems caused by the global pandemic. At the same time, many healthcare companies that would not necessarily have traditionally been considered tech companies have turned their attention to technology and its potential to transform the delivery of their pro

India Emerging as a Next Biologic Drug Hub SHUCHI.P.NAHAR The Indian pharmaceutical companies always had strong chemistry skills to work on small molecules to make generic drugs, but they lacked skills, people and ecosystem to work on large molecules to come up with reverse engineered versions of biotech drugs, many experts complain. However, it is beginning to change.   'India: the emerging hub for biologics and biosimilars', the Indian pharmaceutical companies have launched 123 biosimilars and currently have 201 active biosimilars covering multiple indications in the development pipeline. Further, India has 95 approved biosimilars in the domestic market, more than any other country in the world. Biologics are the biological products regulated under the rules of the Food and Drug Administration (FDA). They are used to either diagnose, prevent, treat, or cure various medical conditions.  Significantly, biologics are large, complex, and diverse molecules produced through biotech